Investor profile
Selvedge Venture
Micro-fund
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Selvedge Venture is a London-based impact-focused micro-fund that invests in founders and startups with a mission to alleviate the 'titanic healthcare burden' caused by age-related medical conditions. The firm concentrates on three disease clusters — Metabolic Syndrome (cardiovascular disease, diabetes, fatty liver disease, and obesity), Cancer, and Neurodegenerative Diseases — which together account for over 60% of all human mortality. Selvedge backs Pre-Seed through Series A companies whose core expertise sits at the intersection of Biotechnology and Digital Technologies, specifically leveraging machine learning, integrated data assets, and advanced biotech platforms to transform patient outcomes. The firm is backed by family offices and high-net-worth individuals, and works closely with founders as active portfolio managers, investing both time and capital with conviction.
Notable quotes
“We're thrilled to be part of the Oxford Medical Products' journey and to help develop its unique hydrogel platform technology. At Selvedge Venture, we have a focus on investing to alleviate the vast burden caused by chronic diseases including obesity, cardiovascular disease, diabetes, and fatty liver disease and we have a huge belief that the development and commercialisation of Sirona will be a key piece of this strategy.”
“Exogene's unique combination of AI technology and in-house TCR screening capabilities in the lab sets it apart from both traditional, wet-lab based TCR biotechs and startups leveraging AI. Selvedge Venture is excited to support Exogene during this next stage of growth towards discovering novel cell therapies for cancer.”
“One of the opportunities that really intrigued Alasdair and I was precision therapeutics in the metabolic syndrome-related conditions. These chronic diseases affect half the world's adult population, accounting for almost half of global deaths. All approved therapeutics as of 2021 were 'one size fits all' and there had hitherto been little disruptive innovation in targeted therapeutics, unlike say cancer and rare diseases.”
Team
Robert Thong
Co-Founder & General Partner
Esra Berkol
Chief of Staff / Partner
Serge Faguet
Venture Partner
Karen Oregan
Venture Partner
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Carbometrics | Seed | — | 2024-05-02 |
| BIOS Health | Series A | $20m | 2023-06-22 |
| Multiomic Health | Seed | $6m | 2023-05-04 |
| Exogene | Seed | $2m | 2022-04-26 |
| Ochre Bio | Seed | — | 2021-06-16 |
| Sanome | Seed | — | 2021-09-28 |
| Oxford Medical Products | Seed | $1m | 2021-06 |
| Mesh Bio | Series A | $4m | 2023-10-12 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Khosla Ventures | 2 |
| Ada Ventures | 2 |
| Heal Capital | 1 |
| R42 Group | 1 |
| XTX Ventures | 1 |
| Hoxton Ventures | 1 |
Fit check
Is Selvedge Venture a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit